NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) announced that its NEREUS™ branded No. 47 IndyCar, fielded by Rahal Letterman Lanigan Racing and driven by Mick Schumacher, will compete in the inaugural Freedom 250 Grand Prix of Washington, D.C., held August 22–23, 2026 on the National Mall.
NEREUS™ (tradipitant), described by Vanda as the first new U.S. prescription medication in 47 years approved to prevent motion-induced vomiting, is the primary sponsor of the No. 47 Honda. The race weekend serves as a home event for the Washington-based company and will be broadcast live on FOX.
Key Figures
- Event dates
- August 22–23, 2026
- Freedom 250 Grand Prix
- Anniversary
- 250th anniversary
- America's anniversary celebration
- Circuit length
- 1.7 miles
- Temporary street circuit
- Circuit turns
- 7 turns
- Temporary street circuit
- Race distance
- 147 laps
- Sunday race
- Race length
- approximately 250 miles
- Sunday race
- New treatment interval
- 47 years
- Since the first new U.S. prescription medication for prevention of motion-induced vomiting
Historical Context
-
Mixed quarterly sales and loss results accompanied by a small positive reaction.
-
Scheduled Q2 results release and conference call announcement preceded positive reaction.
-
EMA positive opinion recommended orphan designation for imsidolimab in generalized pustular psoriasis.
-
NEREUS sponsorship of No. 47 IndyCar entry preceded substantial negative reaction.
-
Scheduled participation in B. Riley summit preceded a negative reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The event, taking place August 22–23, 2026, celebrates America's 250th anniversary with high-speed racing on a 1.7-mile, seven-turn temporary street circuit framed by the Washington Monument,
NEREUS™ (tradipitant), the first new
"Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda.
Fans can follow the No. 47 NEREUS™ IndyCar as Schumacher and Rahal Letterman Lanigan Racing take on this landmark street circuit in the nation's capital.
About NEREUS™ (tradipitant)
NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com and follow us on X @vandapharma.
About Rahal Letterman Lanigan Racing
Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-sponsored-no-47-indycar-ready-for-historic-freedom-250-grand-prix-in-washington-dc-302857737.html
SOURCE Vanda Pharmaceuticals Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.